| Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma (NCT05366829) | Rutgers, The State University of New Jersey | 2022-07-25 |
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (NCT05461430) | Travera Inc | 2022-07-15 |
| Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Patients With Advanced Liver Cancer (NCT05383066) | Peking University First Hospital | 2022-05-20 |
| Possible Differences in HCC Course Depending on DAA Treatment (NCT05376943) | Medical University of Warsaw | 2022-05-10 |
| A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (NCT05337137) | Bristol-Myers Squibb | 2022-05-05 |
| Vascular Invasion Signatures in cfDNA Support Re-staging of Liver Cancer (NCT05540925) | Eastern Hepatobiliary Surgery Hospital | 2022-01-01 |
| Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery (NCT04962958) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-12-27 |
| A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors (NCT05091346) | Eisai Inc. | 2021-10-27 |
| Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures (NCT04970212) | Techsomed Medical Technologies LTD | 2021-09-24 |
| A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy (NCT04732286) | Hoffmann-La Roche | 2021-05-04 |
| Assessment of the Impact of Acquisition Time, Respiratory Gating and New Qclear Reconstruction Modalities on the Quantification of Dosimetry in Selective Internal Radiotherapy (NCT04903340) | University Hospital, Bordeaux | 2021-04-12 |
| A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma (NCT04763408) | Eisai Inc. | 2021-04-09 |
| A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC (NCT04297254) | Eisai Pharmaceuticals India Pvt. Ltd | 2021-02-04 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors (NCT04660929) | Carisma Therapeutics Inc | 2021-02-02 |
| HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT (NCT04618367) | Sun Yat-sen University | 2021-01-01 |
| A Study of PTX-9908 Injection for Non-resectable HCC with TACE (NCT03812874) | TCM Biotech International Corp. | 2020-10-06 |
| TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong) (NCT04560751) | Zhejiang Cancer Hospital | 2020-09-30 |
| A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases (NCT04338685) | Hoffmann-La Roche | 2020-07-16 |
| Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma (NCT04310709) | Asan Medical Center | 2020-06-16 |
| Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) (NCT04246177) | Merck Sharp & Dohme LLC | 2020-05-22 |
| Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas (NCT05352204) | Zhejiang University | 2020-04-30 |
| Atezolizumab Plus Bevacizumab With HCC and HBV Infection (NCT04180072) | National Health Research Institutes, Taiwan | 2020-03-12 |
| RFA Using Combined Bipolar and Monopolar Energy Deliver With Twin Cooled-Wet Electrodes (NCT04331184) | Seoul National University Hospital | 2020-01-28 |
| RFA Using Gradual RF Energy Delivery Mode With Octopus Electrodes (NCT04471272) | Seoul National University Hospital | 2020-01-06 |
| A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (NCT04102098) | Hoffmann-La Roche | 2019-12-31 |
| Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma (NCT04803019) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2019-12-04 |
| CT Imaging for Guiding PA-TACE for HCC (NCT06156748) | Zhujiang Hospital | 2019-10-01 |
| A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma (NCT02939807) | Medical University of South Carolina | 2019-09-30 |
| Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma (NCT03894917) | The University of Texas Health Science Center at San Antonio | 2019-09-13 |
| TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients (NCT04066543) | Zhejiang Cancer Hospital | 2019-08-30 |
| ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma (NCT03897543) | Abivax S.A. | 2019-08-30 |
| A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (NCT04008797) | Eisai Inc. | 2019-07-11 |
| Low-contrast Dose Liver CT Using Lean Body Weight Low Monoenergetic Images and Deep Learning-based Reconstruction (NCT04027556) | Seoul National University Hospital | 2019-06-27 |
| Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC (NCT03939975) | Sun Yat-sen University | 2019-06-01 |
| A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants (NCT05225207) | Eisai Korea Inc. | 2019-05-28 |
| Case-Control Study of the Glycotest™ HCC Panel Vs AFP for the Detection of Early-stage Hepatocellular Carcinoma (NCT03878550) | Glycotest, Inc. | 2019-05-22 |
| A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma (NCT04008082) | Eisai Co., Ltd. | 2019-05-14 |
| A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor Thrombi (NCT03939845) | Shanghai Zhongshan Hospital | 2019-04-23 |
| Randomized Control Trial (RCT) of Early Palliative Care for HCC (NCT02556619) | The University of Texas Health Science Center, Houston | 2019-04-02 |
| A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer (NCT03941873) | BeiGene | 2019-02-28 |
| Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) (NCT03713593) | Merck Sharp & Dohme LLC | 2018-12-31 |
| Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma (NCT03732547) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2018-10-22 |
| A Study on the Angioarchitecture of Hepatocellular Carcinoma (NCT03808766) | Chinese University of Hong Kong | 2018-08-13 |
| Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion (NCT03727633) | University Hospital, Montpellier | 2018-07-19 |
| Prospective Surveillance for Very Early Hepatocellular Carcinoma (NCT03588442) | Eastern Hepatobiliary Surgery Hospital | 2018-07-15 |
| Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma (NCT03662841) | Chinese University of Hong Kong | 2018-07-13 |
| A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma (NCT03663114) | Eisai Inc. | 2018-07-02 |
| Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC (NCT03347292) | Bayer | 2018-06-18 |
| Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma (NCT03572582) | AIO-Studien-gGmbH | 2018-06-14 |
| Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma (NCT03636607) | Fifth Affiliated Hospital, Sun Yat-Sen University | 2018-06-13 |
| Safety and Efficacy of "Immuncell-LC" in TACE Therapy (NCT02856815) | GC Cell Corporation | 2018-05-28 |
| Microwave Ablation Versus Liver Resection For Early Hepatocellular Carcinoma in Patients With Borderline Liver Function (NCT03766555) | Chinese University of Hong Kong | 2018-05-21 |
| Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC) (NCT03433703) | Eisai Inc. | 2018-04-26 |
| Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5 (NCT02582918) | University of Texas Southwestern Medical Center | 2018-03-26 |
| Study to Evaluate VORTX Rx (Theresa) (NCT03741088) | HistoSonics, Inc. | 2018-03-21 |
| A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (NCT03434379) | Hoffmann-La Roche | 2018-03-15 |
| Effect of DAAs on Behavior of HCC in HCV Patients (NCT03200171) | Al-Azhar University | 2018-02-10 |
| A Study to Evaluate Efficacy and Safety of TheraSphere and Resection Combination Therapy in Patients With Single Large ((> 5cm, Long Diameter ) Hepatocellular Carcinoma : Exploratory Trial (NCT05038397) | MedicalExcellence | 2018-01-30 |
| A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma (NCT03418922) | Eisai Co., Ltd. | 2018-01-16 |
| Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma in Korea (NCT03586050) | Ethicon, Inc. | 2017-12-11 |
| TATE Versus TACE in Intermediate Stage HCC (NCT03145558) | Teclison Ltd. | 2017-12-05 |
| Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment (NCT03389126) | Seoul National University Hospital | 2017-12-01 |
| Meclizine for Hepatocellular Carcinoma (NCT03253289) | Tannaz Armaghnay | 2017-10-13 |
| A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100) (NCT03289533) | Pfizer | 2017-09-08 |
| Paediatric Hepatic International Tumour Trial (NCT03017326) | University of Birmingham | 2017-08-24 |
| Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection (NCT03261791) | Shanghai Zhongshan Hospital | 2017-07-20 |
| Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies (NCT03291379) | Boston Scientific Corporation | 2017-05-17 |
| Randomized Trial Comparing Stereotactic Body Radiation Therapy to Microwave Ablation for the Treatment of Localized Hepatocellular Carcinoma (NCT03168152) | University of Michigan Rogel Cancer Center | 2017-05-11 |
| Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394) (NCT03062358) | Merck Sharp & Dohme LLC | 2017-04-27 |
| A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART) (NCT03130712) | Shanghai GeneChem Co., Ltd. | 2017-04-01 |
| Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib (NCT02847468) | Centre Georges Francois Leclerc | 2017-03-27 |
| Needle Guiding Robot for Radiofrequency Ablation: Safety and Efficacy Study on Hepatocellular Carcinoma Patients (NCT03005756) | Asan Medical Center | 2017-01-25 |
| Circulating Tumor Cells and Tumor DNA in HCC and NET (NCT02973204) | University of Aarhus | 2016-11-01 |
| RFA for Small HCC With No-touch Technique Using Octopus Electrode (NCT02832882) | Seoul National University Hospital | 2016-10-21 |
| Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT Patients (NCT02813096) | Guangxi Medical University | 2016-10-01 |
| A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib (NCT03008512) | Gachon University Gil Medical Center | 2016-10-01 |
| A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) (NCT02859324) | Celgene | 2016-09-20 |
| Dynamic Contrast Enhanced HCC SABR Liver Study (NCT02847767) | British Columbia Cancer Agency | 2016-07-01 |
| RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode (NCT02806076) | Seoul National University Hospital | 2016-07-01 |
| A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy (NCT02959151) | Shanghai GeneChem Co., Ltd. | 2016-07-01 |
| Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma (NCT02779465) | Third Affiliated Hospital, Sun Yat-Sen University | 2016-06-01 |
| DCE-MRI for Assessment of Response to TACE of HCC (NCT02878109) | Centre hospitalier de l'Université de Montréal (CHUM) | 2016-06-01 |
| A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC) (NCT02564614) | Hoffmann-La Roche | 2016-05-02 |
| HBV-host cfDNA as Minimal Residual Tumor Marker for HBV-related HCC (NCT03020342) | National Taiwan University Hospital | 2016-05-01 |
| A Study of GPC3 Redirected Autologous T Cells for Advanced HCC (NCT02715362) | Shanghai GeneChem Co., Ltd. | 2016-03-01 |
| Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) (NCT02716766) | The University of Hong Kong | 2016-03-01 |
| Effect of Enhanced Recovery After Surgery(ERAS) After Liver Resection for Primary Liver Cancer (NCT02644603) | Shanghai Zhongshan Hospital | 2016-02-01 |
| Proton Radiotherapy Versus Radiofrequency Ablation for Patients With Medium or Large Hepatocellular Carcinoma (NCT02640924) | Chang Gung Memorial Hospital | 2016-01-01 |
| Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation (NCT02631499) | Fudan University | 2015-12-01 |
| Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma (NCT01171482) | Seoul National University Hospital | 2015-11-01 |
| Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study (NCT02635347) | Rutgers, The State University of New Jersey | 2015-11-01 |
| Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response (NCT02439008) | Centre Oscar Lambret | 2015-09-16 |
| Fingerprint Characterization of Advanced HCC (NCT02372162) | University Hospital Tuebingen | 2015-07-01 |
| MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma (NCT02448056) | National Taiwan University Hospital | 2015-06-01 |
| Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma (NCT02421185) | Janssen Research & Development, LLC | 2015-05-25 |
| HR Versus RFA for HCC in Patients With PHT (NCT02192671) | Guangxi Medical University | 2015-05-01 |
| Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer (NCT02323906) | Celgene | 2015-01-16 |
| Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load (NCT02308319) | Samsung Medical Center | 2015-01-01 |
| RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System (NCT02312817) | University of Texas Southwestern Medical Center | 2014-12-01 |
| TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer (NCT02794337) | Tata Memorial Hospital | 2014-12-01 |